Corcept Therapeutics (CORT) EBIT (2010 - 2026)
Corcept Therapeutics (CORT) posted EBIT of $41.3 million for Q2 2026, up 183.26% sequentially from -$49.6 million in Q1 2026, and up 54.83% YoY from $26.7 million in Q2 2025.
Corcept Therapeutics (CORT) EBIT (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported EBIT for 17 years, with the latest figure at $41.3 million in Q2 2026.
- Quarterly EBIT rose 54.83% year-over-year to $41.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.4 million (down 93.72% YoY) and the FY2025 annual result came in at $44.8 million, down 67.29% from the prior year.
- EBIT improved to $41.3 million in Q2 2026 per CORT's latest filing, from -$49.6 million in the prior quarter.
- Over five years, EBIT peaked at $46.6 million in Q3 2024 and troughed at -$49.6 million in Q1 2026.
- A 5-year average of $21.9 million and a median of $28.1 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2026: EBIT jumped 98.61% in 2024, then tumbled 1552.02% in 2026.
- Over 5 years, EBIT stood at $22.5 million in 2022, then jumped by 40.76% to $31.7 million in 2023, then decreased by 20.23% to $25.3 million in 2024, then sank by 82.24% to $4.5 million in 2025, then jumped by 820.44% to $41.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered $41.3 million, -$49.6 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 41.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.30 Mn |
| Mar 31, 2026 | -49.60 Mn |
| Dec 31, 2025 | 4.49 Mn |
| Sep 30, 2025 | 10.22 Mn |
| Jun 30, 2025 | 26.68 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 25.26 Mn |
| Sep 30, 2024 | 46.60 Mn |
| Jun 30, 2024 | 35.59 Mn |
| Mar 31, 2024 | 29.50 Mn |
| Dec 31, 2023 | 31.67 Mn |
| Sep 30, 2023 | 31.18 Mn |
| Jun 30, 2023 | 29.58 Mn |
| Mar 31, 2023 | 14.85 Mn |
| Dec 31, 2022 | 22.50 Mn |
| Sep 30, 2022 | 31.93 Mn |
| Jun 30, 2022 | 31.43 Mn |
| Mar 31, 2022 | 26.77 Mn |
| Dec 31, 2021 | 36.66 Mn |
| Sep 30, 2021 | 36.23 Mn |